Form 4: LENZ Therapeutics Director, Zachary Scheiner, Acquires Stock Options

Director Zachary Scheiner acquired stock options for LENZ Therapeutics, though disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• Zachary Scheiner, a director of LENZ Therapeutics, acquired stock options on March 21, 2024.
• The options grant the right to buy 27,000 shares of LENZ Therapeutics common stock at an exercise price of $15.05 per share.
• The options vest monthly over three years, starting March 21, 2024, contingent on Scheiner's continued service.
• Scheiner disclaims beneficial ownership of the options and underlying stock because they are held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus II Fund, and a separately managed account.
• Any proceeds from the options will offset advisory fees owed by these entities to RA Capital Management.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants.

Future Outlook

The options vest over time, incentivizing continued service from the director.

Industry Context

Form 4 filings are standard disclosures for corporate insiders, providing transparency into their transactions in company stock.

Related Party Transactions

• The arrangement between Zachary Scheiner, RA Capital Management, RA Capital Healthcare Fund, RA Capital Nexus II Fund, and the separately managed account constitutes a related party transaction.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, incentivizing value creation.
• The arrangement with RA Capital Management impacts the advisory fees paid by the Fund, Nexus II Fund, and the Account.

Key Dates